Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

May 15, 2026

Consolidated Financial Results for the Fiscal Year Ended March 31, 2026(Under Japanese GAAP)

Company name: EnBio Holdings, Inc
Listing: Tokyo Stock Exchange
Securities code: 6092
URL: https://enbio-holdings.com/
Representative: Yoshikazu Nakamura, President & Chief Executive Officer
Inquiries: Masahiro Tanaka, General Manager of Accounting Dept.
Telephone: 03-5297-7155
Scheduled date of annual general meeting of shareholders: June 26, 2026
Scheduled date to commence dividend payments: June 12, 2026
Scheduled date to file annual securities report: June 25, 2026
Preparation of supplementary material on financial results: Yes
Holding of financial results briefing: Yes

(Yen amounts are rounded down to millions, unless otherwise noted.)

1.Consolidated financial results for the fiscal year ended March 31, 2026 (from April 1, 2025 to March 31, 2026)

(1) Consolidated operating results

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Fiscal year ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
March 31, 2026	12,630	18.4	1,619	92.9	1,598	127.7	265	(41.4)
March 31, 2025	10,668	11.4	839	3.0	702	(34.2)	452	(36.1)

Note: Comprehensive income
For the fiscal year ended March 31, 2026 ¥153 million [(78.3%)]
For the fiscal year ended March 31, 2025 ¥708 million [(4.1%)]

	Basic earnings per share	Diluted earnings per share	Return on equity	Ratio of ordinary profit to total assets	Ratio of operating profit to net sales
Fiscal year ended	Yen	Yen	%	%	%
March 31, 2026	32.73	–	2.9	7.3	12.8
March 31, 2025	55.90	–	5.1	3.5	7.9

Reference: Share of profit (loss) of entities accounted for using equity method
For the fiscal year ended March 31, 2026 - million
For the fiscal year ended March 31, 2025 - million

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
March 31, 2026	22,848	9,326	40.5	1,139.31
March 31, 2025	21,195	9,230	43.1	1,128.81

Reference: Equity
As of March 31, 2026 ¥9,248 million
As of March 31, 2025 ¥9,141 million

(3) Consolidated cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
Fiscal year ended	Millions of yen	Millions of yen	Millions of yen	Millions of yen
March 31, 2026	1,167	(895)	464	4,006
March 31, 2025	21	(1,602)	1,274	3,263

2.Cash dividends

	Annual dividends per share					Total cash dividends (Total)	Payout ratio (Consolidated)	Ratio of dividends to net assets (Consolidated)
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total			
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Fiscal year ended March 31, 2025	-	0.00	-	9.00	9.00	72	16.1	0.8
Fiscal year ended March 31, 2026	-	0.00	-	9.00	9.00	73	27.5	0.8
Fiscal year ending March 31, 2027 (Forecast)	-	0.00	-	24.00	24.00		28.2	

3.Forcast of consolidated financial results for the year ending March 31, 2027 (from April 1, 2026 to March 31, 2027) (Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full Year	13,630	7.9	1,220	(24.7)	1,060	(33.7)	690	160.1	85.12

***Notes**

(1) Significant changes in the scope of consolidation during the period: Yes

Newly included: 1 company (EnBio NExTeS, Inc.)

(2) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

(3) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of March 31, 2026	8,175,200 shares
As of March 31, 2025	8,175,200 shares

(ii) Number of treasury shares at the end of the period

As of March 31, 2026	57,605 shares
As of March 31, 2025	75,090 shares

(iii) Average number of shares outstanding during the period

Fiscal year ended March 31, 2026	8,105,737 shares
Fiscal year ended March 31, 2025	8,098,894 shares

[Reference] Overview of non-consolidated financial results

1.Non-consolidated financial results for the fiscal year ended March 31, 2026 (from April 1, 2025 to March 31, 2026)

(1) Non-consolidated operating results (Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit	
Fiscal year ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
March 31, 2026	951	24.2	97	-	350	-	63	(25.5)
March 31, 2025	765	(5.7)	(16)	-	30	(92.3)	84	(77.7)

	Basic earnings per share	Diluted earnings per share
Fiscal year ended	Yen	Yen
March 31, 2026	7.79	-
March 31, 2025	10.47	-

(2) Non-consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
March 31, 2026	10,866	5,609	51.6	690.98
March 31, 2025	10,859	5,568	51.3	687.51

Reference:Equity

As of March 31, 2026: ¥5,609 million

As of March 31, 2025: ¥5,568 million

Reasons for the differences in the full-year non-consolidated financial results between the fiscal year ended March 31, 2026 and the previous fiscal year

The differences in the actual results of non-consolidated financial results between the fiscal year ended March 31, 2026 and the previous fiscal year are due to the increased dividends from consolidated subsidiaries and the sharp depreciation of the yen in the exchange rate.

*Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or audit firm: None

*Proper use of earnings forecasts, and other special matters

Notes on the use of forward-looking statements

Forward-looking statements that include forecasts of business results are based on the information currently available and certain assumptions judged to be rational.
The Company makes no guarantee that these figures will be achieved. Actual business results may differ substantially because of various factors.

Changing the display unit of the amount

The amounts of items and other matters listed in the Company's consolidated financial statements were previously stated in units of 1 thousand yen, but have been changed to in units of 1 million yen from the current fiscal year.
For ease of comparison, the consolidated accouting period of the previous fiscal year have also been changed to units of 1 million yen.

Consolidated Financial Statements

Consolidated Balance Sheet

(Millions of yen)

	As of March 31, 2025	As of March 31, 2026
Assets		
Current assets		
Cash and deposits	3,293	4,036
Notes and accounts receivable - trade, and contract assets	2,354	2,309
Inventories	2,952	4,445
Other	357	618
Allowance for doubtful accounts	(0)	(0)
Total current assets	8,957	11,409
Non-current assets		
Property, plant and equipment		
Buildings and structures	1,178	876
Accumulated depreciation	(310)	(200)
Buildings and structures, net	868	675
Machinery, equipment and vehicles	7,531	8,545
Accumulated depreciation	(1,838)	(2,350)
Machinery, equipment and vehicles, net	5,692	6,195
Land	1,819	1,444
Construction in progress	437	434
Other	41	56
Accumulated depreciation	(32)	(35)
Other, net	9	21
Total property, plant and equipment	8,827	8,771
Intangible assets		
Goodwill	94	86
Other	351	331
Total intangible assets	445	417
Investments and other assets		
Investment securities	836	368
Long-term loans receivable	1,561	1,920
Leasehold and guarantee deposits	93	97
Long-term prepaid expenses	303	302
Other	169	251
Allowance for doubtful accounts	-	(690)
Total investments and other assets	2,964	2,249
Total non-current assets	12,237	11,438
Total assets	21,195	22,848

(Millions of yen)

	As of March 31, 2025	As of March 31, 2026
Liabilities		
Current liabilities		
Accounts payable - trade	744	1,161
Accounts payable - other, and accrued expenses	110	145
Short-term borrowings	1,788	972
Current portion of long-term borrowings	1,666	1,915
Income taxes payable	199	553
Contract liabilities	209	301
Provision for bonuses	41	65
Provision for loss on construction contracts	0	-
Other	56	67
Total current liabilities	4,818	5,182
Non-current liabilities		
Long-term borrowings	6,643	7,766
Asset retirement obligations	295	375
Other	206	197
Total non-current liabilities	7,146	8,339
Total liabilities	11,964	13,521
Net assets		
Shareholders' equity		
Share capital	2,325	2,325
Capital surplus	2,404	2,412
Retained earnings	4,149	4,341
Treasury shares	(38)	(35)
Total shareholders' equity	8,840	9,043
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	2	16
Deferred gains or losses on hedges	28	72
Foreign currency translation adjustment	270	115
Total accumulated other comprehensive income	301	204
Non-controlling interests	89	78
Total net assets	9,230	9,326
Total liabilities and net assets	21,195	22,848

Consolidated Statement of Income and Comprehensive Income

Consolidated Statement of Income

(Millions of yen)

	Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026
Net sales	10,668	12,630
Cost of sales	8,014	8,942
Gross profit	2,653	3,688
Selling, general and administrative expenses	1,814	2,069
Operating profit	839	1,619
Non-operating income		
Interest and dividend income	60	60
Rental income from buildings	6	6
Insurance claim income	17	5
Foreign exchange gains	-	100
Reversal of allowance for doubtful accounts	8	-
Other	10	10
Total non-operating income	102	183
Non-operating expenses		
Interest expenses	141	179
Commission expenses	36	14
Foreign exchange losses	27	-
Other	35	10
Total non-operating expenses	239	203
Ordinary profit	702	1,598
Extraordinary income		
Subsidy income	9	-
Gain on sale of investment securities	-	238
Total extraordinary income	9	238
Extraordinary losses		
Loss on sale of non-current assets	-	0
Loss on retirement of non-current assets	-	1
Loss on tax purpose reduction entry of non-current assets	9	-
Loss on withdrawal from business	-	919
Total extraordinary losses	9	921
Profit before income taxes	702	915
Income taxes - current	329	703
Income taxes - deferred	(47)	(40)
Total income taxes	281	663
Profit	420	252
Loss attributable to non-controlling interests	(32)	(13)
Profit attributable to owners of parent	452	265

Consolidated Statement of Comprehensive Income

(Millions of yen)

	Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026
Profit	420	252
Other comprehensive income		
Valuation difference on available-for-sale securities	(22)	14
Deferred gains or losses on hedges	50	44
Foreign currency translation adjustment	260	(157)
Total other comprehensive income	288	(98)
Comprehensive income	708	153
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	737	168
Comprehensive income attributable to non-controlling interests	(29)	(14)

Consolidated Statement of Changes in Net Assets

Fiscal year ended March 31, 2025 (from April 1, 2024 to March 31, 2025)

(Millions of yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	2,325	2,405	3,761	(15)	8,476
Changes during period					
Dividends of surplus			(65)		(65)
Profit attributable to owners of parent			452		452
Purchase of treasury shares				(34)	(34)
Disposal of treasury shares		(0)		11	10
Net changes in items other than shareholders' equity					
Total changes during period	-	(0)	387	(23)	363
Balance at end of period	2,325	2,404	4,149	(38)	8,840

	Accumulated other comprehensive income				Non-controlling interests	Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustment	Total accumulated other comprehensive income		
Balance at beginning of period	24	(21)	14	17	96	8,591
Changes during period						
Dividends of surplus						(65)
Profit attributable to owners of parent						452
Purchase of treasury shares						(34)
Disposal of treasury shares						10
Net changes in items other than shareholders' equity	(22)	50	255	283	(7)	275
Total changes during period	(22)	50	255	283	(7)	638
Balance at end of period	2	28	270	301	89	9,230

Fiscal year ended March 31, 2026 (from April 1, 2025 to March 31, 2026)

(Millions of yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	2,325	2,404	4,149	(38)	8,840
Changes during period					
Dividends of surplus			(72)		(72)
Profit attributable to owners of parent			265		265
Purchase of treasury shares				(0)	(0)
Disposal of treasury shares		7		3	11
Net changes in items other than shareholders' equity					
Total changes during period	-	7	192	3	203
Balance at end of period	2,325	2,412	4,341	(35)	9,043

	Accumulated other comprehensive income				Non-controlling interests	Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustment	Total accumulated other comprehensive income		
Balance at beginning of period	2	28	270	301	89	9,230
Changes during period						
Dividends of surplus						(72)
Profit attributable to owners of parent						265
Purchase of treasury shares						(0)
Disposal of treasury shares						11
Net changes in items other than shareholders' equity	14	44	(155)	(96)	(10)	(107)
Total changes during period	14	44	(155)	(96)	(10)	96
Balance at end of period	16	72	115	204	78	9,326

Consolidated Statement of Cash Flows

(Millions of yen)

	Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026
Cash flows from operating activities		
Profit before income taxes	702	915
Depreciation	479	535
Loss on withdrawal from business	-	919
Amortization of goodwill	18	8
Increase (decrease) in allowance for doubtful accounts	(11)	(0)
Interest and dividend income	(60)	(60)
Interest expenses	141	179
Foreign exchange losses (gains)	26	(101)
Subsidy income	(9)	-
Insurance claim income	(17)	(3)
Loss (gain) on sale of investment securities	-	(238)
Loss on tax purpose reduction entry of non-current assets	9	-
Loss (gain) on sale of non-current assets	-	0
Loss on retirement of non-current assets	-	1
Decrease (increase) in trade receivables	(1,068)	44
Decrease (increase) in inventories	184	(905)
Increase (decrease) in trade payables	(152)	416
Increase (decrease) in contract liabilities	(161)	91
Other, net	209	(136)
Subtotal	291	1,664
Interest and dividends received	16	18
Interest paid	(141)	(174)
Proceeds from insurance income	17	3
Income taxes refund (paid)	(161)	(345)
Net cash provided by (used in) operating activities	21	1,167
Cash flows from investing activities		
Payments into time deposits	(0)	(0)
Purchase of shares of subsidiaries and associates	(29)	-
Purchase of property, plant and equipment	(1,462)	(1,048)
Proceeds from sale of property, plant and equipment	-	0
Purchase of intangible assets	(5)	(5)
Purchase of investment securities	(3)	(3)
Proceeds from sale of investment securities	-	585
Proceeds from withdrawal of investment securities	8	4
Purchase of long-term prepaid expenses	(1)	(16)
Loan advances	(121)	(426)
Proceeds from collection of loans receivable	-	23
Subsidies received	9	-
Other, net	1	(10)
Net cash provided by (used in) investing activities	(1,602)	(895)
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	786	(816)
Proceeds from long-term borrowings	2,529	3,724
Repayments of long-term borrowings	(1,906)	(2,351)
Commission expenses paid	(35)	(23)
Purchase of treasury shares	(34)	-
Proceeds from share issuance to non-controlling shareholders	-	4
Dividends paid	(65)	(72)
Net cash provided by (used in) financing activities	1,274	464
Effect of exchange rate change on cash and cash equivalents	(4)	8
Net increase (decrease) in cash and cash equivalents	(311)	743
Cash and cash equivalents at beginning of period	3,574	3,263
Increase in cash and cash equivalents resulting from inclusion of subsidiaries in consolidation	0	-
Cash and cash equivalents at end of period	3,263	4,006